The burgeoning role of paclitaxel in advanced pulmonary malignancy

Corey J. Langer, David S Ettinger

Research output: Contribution to journalArticle

Abstract

Historically, the treatment of advanced non-small cell lung cancer (NSCLC) with cisplatin-based therapy has been a nearly futile effort. Median survival was seldom greater than six months, and fewer than 20% of those with metastatic NSCLC survived more than one year. In addition, toxicity often equaled, if not exceeded, benefit. Over the past five years, however, we have witnessed an explosion of new agents in advanced lung carcinoma. These new agents - in particular the taxanes, gemcitabine, vinorelbine, and topoisomerase I inhibitors - have breathed new life into clinical research. The therapeutic gains, though modest, are real. Paclitaxel, to a large extent, given either alone or in combination with platinols, has led the charge.

Original languageEnglish (US)
Pages (from-to)67-85
Number of pages19
JournalOncologist
Volume3
Issue number2
StatePublished - 1998

Fingerprint

gemcitabine
Paclitaxel
Non-Small Cell Lung Carcinoma
Cisplatin
Topoisomerase I Inhibitors
Taxoids
Lung
Explosions
Neoplasms
Carcinoma
Therapeutics
Research
vinorelbine

Keywords

  • Chemotherapy
  • Metastatic disease
  • NSCLC (Non-small cell lung cancer)
  • Paclitaxel
  • Paclitaxel-carboplatin combination

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Cite this

The burgeoning role of paclitaxel in advanced pulmonary malignancy. / Langer, Corey J.; Ettinger, David S.

In: Oncologist, Vol. 3, No. 2, 1998, p. 67-85.

Research output: Contribution to journalArticle

@article{2c289d2888664fe18e48b3a331a27f02,
title = "The burgeoning role of paclitaxel in advanced pulmonary malignancy",
abstract = "Historically, the treatment of advanced non-small cell lung cancer (NSCLC) with cisplatin-based therapy has been a nearly futile effort. Median survival was seldom greater than six months, and fewer than 20{\%} of those with metastatic NSCLC survived more than one year. In addition, toxicity often equaled, if not exceeded, benefit. Over the past five years, however, we have witnessed an explosion of new agents in advanced lung carcinoma. These new agents - in particular the taxanes, gemcitabine, vinorelbine, and topoisomerase I inhibitors - have breathed new life into clinical research. The therapeutic gains, though modest, are real. Paclitaxel, to a large extent, given either alone or in combination with platinols, has led the charge.",
keywords = "Chemotherapy, Metastatic disease, NSCLC (Non-small cell lung cancer), Paclitaxel, Paclitaxel-carboplatin combination",
author = "Langer, {Corey J.} and Ettinger, {David S}",
year = "1998",
language = "English (US)",
volume = "3",
pages = "67--85",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "2",

}

TY - JOUR

T1 - The burgeoning role of paclitaxel in advanced pulmonary malignancy

AU - Langer, Corey J.

AU - Ettinger, David S

PY - 1998

Y1 - 1998

N2 - Historically, the treatment of advanced non-small cell lung cancer (NSCLC) with cisplatin-based therapy has been a nearly futile effort. Median survival was seldom greater than six months, and fewer than 20% of those with metastatic NSCLC survived more than one year. In addition, toxicity often equaled, if not exceeded, benefit. Over the past five years, however, we have witnessed an explosion of new agents in advanced lung carcinoma. These new agents - in particular the taxanes, gemcitabine, vinorelbine, and topoisomerase I inhibitors - have breathed new life into clinical research. The therapeutic gains, though modest, are real. Paclitaxel, to a large extent, given either alone or in combination with platinols, has led the charge.

AB - Historically, the treatment of advanced non-small cell lung cancer (NSCLC) with cisplatin-based therapy has been a nearly futile effort. Median survival was seldom greater than six months, and fewer than 20% of those with metastatic NSCLC survived more than one year. In addition, toxicity often equaled, if not exceeded, benefit. Over the past five years, however, we have witnessed an explosion of new agents in advanced lung carcinoma. These new agents - in particular the taxanes, gemcitabine, vinorelbine, and topoisomerase I inhibitors - have breathed new life into clinical research. The therapeutic gains, though modest, are real. Paclitaxel, to a large extent, given either alone or in combination with platinols, has led the charge.

KW - Chemotherapy

KW - Metastatic disease

KW - NSCLC (Non-small cell lung cancer)

KW - Paclitaxel

KW - Paclitaxel-carboplatin combination

UR - http://www.scopus.com/inward/record.url?scp=0031923549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031923549&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0031923549

VL - 3

SP - 67

EP - 85

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 2

ER -